Cardiff Oncology Share Price Today
(NASDAQ: CRDF)

Name: Cardiff Oncology Share Price Today (NASDAQ: CRDF) - Cardiff Oncology Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Cardiff Oncology share price is $2.74 & ₹232.04 as on 1 May 2025, 2.30 'hrs' IST

$2.74

▲

-0.04

(-1.44%)

Market is closed - opens 7 PM, 01 May 2025

View live Cardiff Oncology share price in Dollar and Rupees. Guide to invest in Cardiff Oncology stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cardiff Oncology, along with analyst recommendations, forecasts, and comprehensive financials.

Cardiff Oncology share price movements

Today's Low: $2.69
Today's High: $2.79
$2.74
1.82%
Downside
Day's Volatility :3.58%
Upside
1.79%
52 Weeks Low: $2.01
52 Weeks High: $5.64
$2.74
26.64%
Downside
52 Weeks Volatility :64.36%
Upside
51.41%

Cardiff Oncology (CRDF) Returns

Period	Cardiff Oncology Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-30.1%	-5.2%	0.0%
6 Months	-11.06%	-5.7%	0.0%
1 Year	-34.4%	-0.9%	0.0%
3 Years	92.71%	6.9%	-5.1%

Cardiff Oncology (CRDF) Key Statistics

in dollars & INR

Previous Close	$2.78
Open	$2.75
Today's High	$2.79
Today's Low	$2.69
Market Capitalization	$196.2M
Today's Volume	$870.9K
52 Week High	$5.6395
52 Week Low	$2.01
Revenue TTM	$683.0K
EBITDA	$-48.2M
Earnings Per Share (EPS)	$-0.97
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-59.51%

How to invest in Cardiff Oncology Stock (CRDF) from India?

It is very easy for Indian residents to invest directly in Cardiff Oncology from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cardiff Oncology stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cardiff Oncology or CRDF on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cardiff Oncology or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cardiff Oncology shares which would translate to 0.309 fractional shares of Cardiff Oncology as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cardiff Oncology, in just a few clicks!

Returns in Cardiff Oncology (CRDF) for Indian investors in Rupees

The Cardiff Oncology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Cardiff Oncology investment value today

Current value as on today

₹66,243

Returns

₹33,757

(-33.76%)

Returns from Cardiff Oncology Stock

₹35,225 (-35.22%)

Dollar Returns

₹1,467 (+1.47%)

Indian investors sentiment towards Cardiff Oncology (CRDF)

115%

Period: Mar 31, 2025 to Apr 30, 2025. Change in 30 Days versus previous period

Search interest for Cardiff Oncology Stock from India on INDmoney has increased by 115% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cardiff Oncology

COMMODORE CAPITAL LP
8.09%
BlackRock Inc
4.27%
Pfizer Inc
3.63%
Vanguard Group Inc
3.43%
Orbimed Advisors, LLC
2.31%
Adage Capital Partners Gp LLC
1.94%

Analyst Recommendation on Cardiff Oncology

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Cardiff Oncology(by analysts ranked 0 to 5 stars)

Analyst Forecast on Cardiff Oncology Stock (CRDF)

What analysts predicted

Upside of 392.7%

Target:

$13.50

Current:

$2.74

Insights on Cardiff Oncology Stock (Ticker Symbol: CRDF)

Price Movement
In the last 3 years, CRDF stock has moved up by 107.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 165.0K → 151.0K (in $), with an average decrease of 8.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -11.85M → -11.78M (in $), with an average increase of 0.6% per quarter
CRDF vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.6% return, outperforming this stock by 106.0%
Price to Sales
ForCRDF every $1 of sales, investors are willing to pay $195.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Cardiff Oncology Technicals Summary

Sell

Neutral

Buy

Cardiff Oncology is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cardiff Oncology (CRDF) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cardiff Oncology Inc	-9.31%	-11.06%	-34.4%	92.71%	128.4%
Biontech Se	14.33%	-7.95%	15.74%	-28.71%	127.41%
Regeneron Pharmaceuticals, Inc.	-7.79%	-32.13%	-37.03%	-12.75%	5.0%
Vertex Pharmaceuticals Incorporated	3.75%	5.66%	25.06%	91.98%	90.0%
Alnylam Pharmaceuticals, Inc.	0.61%	-3.48%	71.59%	85.05%	88.33%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cardiff Oncology Inc	NA	NA	NA	-0.82	-0.6	-0.34	NA	1.25
Biontech Se	160.8	NA	0.04	-5.11	-0.03	-0.04	NA	80.89
Regeneron Pharmaceuticals, Inc.	15.94	15.94	0.96	39.38	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cardiff Oncology Inc	Buy	$196.2M	128.4%	NA	0.0%
Biontech Se	Buy	$29.5B	127.41%	160.8	-24.18%
Regeneron Pharmaceuticals, Inc.	Buy	$66.5B	5.0%	15.94	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$127.6B	90.0%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$33.0B	88.33%	NA	-12.37%

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Organization	Cardiff Oncology
Employees	32
CEO	Dr. Mark Erlander Ph.D.
Industry	Health Services

Management People of Cardiff Oncology

Name	Title
Dr. Mark Erlander Ph.D.	CEO & Director
Mr. James E. Levine	Chief Financial Officer
Dr. Fairooz F. Kabbinavar FACP, M.D.	Chief Medical Officer
Dr. Tod Smeal Ph.D.	Chief Scientific Officer
Ms. Elizabeth Anderson	VP of Finance & Administration
Ms. Brigitte Lindsay	Senior Vice President of Finance
Mr. Charles Monahan R.Ph.	Senior Vice President of Regulatory Affairs

Important FAQs about investing in CRDF Stock from India :

What is Cardiff Oncology share price today?

Cardiff Oncology share price today stands at $2.74, Open: $2.75 ; Previous Close: $2.78 ; High: $2.79 ; Low: $2.69 ; 52 Week High: $5.64 ; 52 Week Low: $2.01.

The stock opens at $2.75, after a previous close of $2.78. The stock reached a daily high of $2.79 and a low of $2.69, with a 52-week high of $5.64 and a 52-week low of $2.01.

Can Indians buy Cardiff Oncology shares?

Yes, Indians can invest in the Cardiff Oncology (CRDF) from India.

With INDmoney, you can buy Cardiff Oncology at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cardiff Oncology at zero transaction cost.

How can I buy Cardiff Oncology shares from India?

It is very easy to buy Cardiff Oncology from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cardiff Oncology (CRDF) be purchased?

Yes, you can buy fractional shares of Cardiff Oncology with INDmoney app.

What are the documents required to start investing in Cardiff Oncology stocks?

To start investing in Cardiff Oncology, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.